1300 856 695
+44 203 514 0688
1800 867 1390If you would like to submit a blog post for consideration, please email admin@healthcert.com
Research Review on Psoriasis [May]
A couple of papers in this research review on psoriasis highlight the increased risk of malignancy associated with the condition. The findings illustrate an increased risk of melanoma and haematological cancers in patients with psoriasis compared with the general population. Notably, this risk is not increased by systemic or biologic psoriasis therapies.
Featured in this issue:
- Safety data differ between RA and psoriasis
- Psoriasis marked by premature mortality
- Brodalumab in generalised pustular psoriasis + psoriatic erythroderma
- Increase skin cancer surveillance in biologics users?
- Psoriasis linked to melanoma and haematological cancers
- Guselkumab vs adalimumab in moderate-to-severe psoriasis
- Ixekizumab maintenance shows acceptable safety in psoriasis
- Few IBD cases with ixekizumab
- Calcipotriol/betamethasone dipropionate gel: maintenance regimens compared
- Apremilast improves PROs in moderate-to-severe psoriasis
Click here to download the full paper
Interested in General Dermatology?
The HealthCert Professional Diploma of General Dermatology will teach you how to manage all major dermatological conditions in primary care. The courses are university quality-assured, CPD-accredited and count towards multiple Master degree pathways and clinical attachment programs in Australia and overseas. The program is delivered online.
1300 856 695
+44 203 514 0688
1800 867 1390
One comment on “Research Review on Psoriasis [May]”